title: Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer: A Systematic Review and Meta-analysis.
abstract: Inflammation is increasingly reported to be associated with the prognosis of patients with cancers. And the prognostic role of neutrophil-to-lymphocyte ratio (NLR) in patients with prostate cancer (PCa) remains inconsistent. Therefore, we conducted this systematic review and meta-analysis to obtain a more reliable assessment of prognostic significance of NLR in PCa.A comprehensive literature research regarding the association of NLR and prognosis of PCa was performed through PubMed, Embase, Cochrane Central, and Web of Science. The hazard ratios (HRs) and its 95% confidence intervals (CIs) for overall survival (OS), progression-free survival, or recurrence-free survival were extracted and pooled using fix-effects model or random-effects model.A total of 14 studies that met our criterion were included in this meta-analysis. Our pooled results demonstrated that elevated NLR was not significantly associated with the poor OS (HR = 1.45; 95% CI 0.77-2.71; P = 0.248) or recurrence-free survival (HR = 1.34; 95% CI 0.89-2.02; P = 0.155) of patients with localized PCa. Although elevated NLR predicted poorer OS (HR = 1.57; 95% CI 1.41-1.74; P < 0.001) and progression-free survival (HR = 1.97; 95% CI 1.28-3.04; P = 0.002) of patients with metastatic castration resistant prostate cancer (mCRPC).Elevated NLR is a strong indicator of poorer prognosis of patients with mCRPC, whereas the NLR is not significantly associated with prognosis of patients with localized PCa. Therefore, NLR could be used in patients with mCRPC for risk stratification and decision making of individual treatment.
authors.affiliation: From the Department of Urology, Chinese PLA General Hospital (XY, FL, SQ, ZY) and Department of Urology, The First Affiliated Hospital of PLA General Hospital, Beijing, China (YX, JG).
authors.forename: Xiaotao
authors.initials: X
authors.lastname: Yin
authors.forename: Yi
authors.initials: Y
authors.lastname: Xiao
authors.forename: Fanglong
authors.initials: F
authors.lastname: Li
authors.forename: Siyong
authors.initials: S
authors.lastname: Qi
authors.forename: Zhaoyang
authors.initials: Z
authors.lastname: Yin
authors.forename: Jiangping
authors.initials: J
authors.lastname: Gao
mesh_terms: D006801:Humans; D007958:Leukocyte Count; D018655:Lymphocyte Count; D008297:Male; D009504:Neutrophils; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000401:mortality
references.citation: Urology. 2007 Nov;70(5):931-5
references.pmid: 18068450
references.citation: Cell. 2011 Mar 4;144(5):646-74
references.pmid: 21376230
references.citation: Br J Cancer. 1973 Aug;28(2):108-17
references.pmid: 4581078
references.citation: Int J Cancer. 2014 May 15;134(10):2403-13
references.pmid: 24122750
references.citation: J Immunol. 1985 Jan;134(1):230-4
references.pmid: 3871101
references.citation: Ann Oncol. 2015 Apr;26(4):750-755
references.pmid: 25538172
references.citation: World J Gastroenterol. 2010 Dec 14;16(46):5790-800
references.pmid: 21154999
references.citation: N Engl J Med. 2011 May 26;364(21):1995-2005
references.pmid: 21612468
references.citation: J Clin Invest. 2010 Apr;120(4):1151-64
references.pmid: 20237412
references.citation: Cancer. 2014 Nov 1;120(21):3346-52
references.pmid: 24995769
references.citation: BMJ. 2003 Sep 6;327(7414):557-60
references.pmid: 12958120
references.citation: J Natl Cancer Inst. 2014 May 29;106(6):dju124
references.pmid: 24875653
references.citation: Int J Urol. 2015 Sep;22(9):827-33
references.pmid: 26087772
references.citation: Br J Cancer. 2011 Jun 28;105(1):93-103
references.pmid: 21629244
references.citation: Clin Genitourin Cancer. 2014 Oct;12(5):317-24
references.pmid: 24806399
references.citation: World J Urol. 2015 Nov;33(11):1661-7
references.pmid: 25617235
references.citation: Biometrics. 1994 Dec;50(4):1088-101
references.pmid: 7786990
references.citation: BJU Int. 2014 Dec;114(6b):E11-E17
references.pmid: 24529213
references.citation: CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
references.pmid: 25559415
references.citation: Clin Transl Oncol. 2012 Nov;14(11):864-9
references.pmid: 22855161
references.citation: Biomarkers. 2010 Sep;15(6):516-22
references.pmid: 20602543
references.citation: Eur Urol. 2006 Apr;49(4):666-74
references.pmid: 16423446
references.citation: Springerplus. 2015 Jun 12;4:255
references.pmid: 26085975
references.citation: J Clin Oncol. 2003 Apr 1;21(7):1232-7
references.pmid: 12663709
references.citation: Cancer. 2008 Jan 1;112(1):69-74
references.pmid: 18000803
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563
references.citation: Asian J Androl. 2014 May-Jun;16(3):467-71
references.pmid: 24589465
references.citation: JAMA. 2000 Apr 19;283(15):2008-12
references.pmid: 10789670
references.citation: BMJ. 2009 Jul 21;339:b2535
references.pmid: 19622551
references.citation: Oncologist. 2012;17(12):1508-14
references.pmid: 22971522
references.citation: Eur Urol. 2011 Aug;60(2):270-8
references.pmid: 21550166
references.citation: BMJ Open. 2015 Apr 08;5(4):e006404
references.pmid: 25854964
references.citation: N Engl J Med. 2010 Jul 29;363(5):411-22
references.pmid: 20818862
references.citation: Ann N Y Acad Sci. 2013 May;1284:1-5
references.pmid: 23651186
references.citation: N Engl J Med. 2012 Sep 27;367(13):1187-97
references.pmid: 22894553
references.citation: Clin Genitourin Cancer. 2013 Dec;11(4):423-30
references.pmid: 23816526
references.citation: Cell. 2010 Mar 19;140(6):883-99
references.pmid: 20303878
references.citation: Proc Natl Acad Sci U S A. 1989 Dec;86(23):9499-503
references.pmid: 2480603
references.citation: Eur Urol. 2011 Aug;60(2):279-90
references.pmid: 21592649